Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
Covington
McKinsey
Moodys
Cantor Fitzgerald
Chubb
Queensland Health
Cipla
Boehringer Ingelheim

Generated: October 20, 2017

DrugPatentWatch Database Preview

ZORTRESS Drug Profile

« Back to Dashboard

Which patents cover Zortress, and what generic Zortress alternatives are available?

Zortress is a drug marketed by Novartis and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in ZORTRESS is everolimus. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the everolimus profile page.

Summary for Tradename: ZORTRESS

US Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list16
Clinical Trials: see list42
Patent Applications: see list7,528
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ZORTRESS at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-001Apr 20, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-002Apr 20, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-001Apr 20, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-003Apr 20, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-002Apr 20, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-001Apr 20, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-001Apr 20, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-002Apr 20, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-002Apr 20, 2010RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-003Apr 20, 2010RXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: ZORTRESS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-003Apr 20, 2010► Subscribe► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-001Apr 20, 2010► Subscribe► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-002Apr 20, 2010► Subscribe► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-003Apr 20, 2010► Subscribe► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-001Apr 20, 2010► Subscribe► Subscribe
Novartis
ZORTRESS
everolimus
TABLET;ORAL021560-002Apr 20, 2010► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for ZORTRESS

Drugname Dosage Strength RLD Submissiondate
everolimusTablets0.25 mg, 0.5 mg, and 0.75 mgZortress9/30/2013
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
US Army
Johnson and Johnson
Federal Trade Commission
Julphar
Novartis
Argus Health
US Department of Justice
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot